FDA Proposes CGMP Framework for Animal Drug Compounding - Lab Manager
FDA proposes a CGMP framework for animal drug compounding, which would impose current good manufacturing practice requirements on compounding facilities.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Animal drug compounding facilities, including those that compound from bulk drug substances or for office stock, and potentially outsourcing facilities. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; the proposal is in the comment period, so monitor for final rule effective date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA is proposing a new CGMP framework specifically for animal drug compounding, which would require compliance with current good manufacturing practices.
Who it affects
Animal drug compounding facilities, including those that compound from bulk drug substances or for office stock, and potentially outsourcing facilities.
What you must do
Review current compounding practices against the proposed CGMP requirements and prepare to implement necessary changes once finalized.
Deadline
Not specified in the excerpt; the proposal is in the comment period, so monitor for final rule effective date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada - kff.org
- Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- FDA Warns Exosome Maker for Marketing Outside Its IND - medpagetoday.com
- GLP‑1 Compliance- FDA Targets Telehealth Marketing in 30 New Warning Letters - natlawreview.com
- Court bans Florida compounder from all manufacturing until it can meet FDA requirements - fiercepharma.com